← Back to Dashboard

SUNPHARMA Sun Pharmaceutical Industries Ltd. — Smart-Money Activity, F&O Buildup & Bulk Deals

Sector: Healthcare · Nifty 50 Weight: 1.66%
₹ 1,788.50
-0.08%

Smart Money Verdict synthesis of derivatives, deals, and promoter files

Derivatives signal Short Buildup
Short sellers are loading fresh positions (OI up +1.4%) on price weakness (-0.1%).

Analysis what the data is telling us about SUNPHARMA

In the last completed session, Sun Pharmaceutical Industries Ltd. closed -0.14% with futures open interest moving +1.4%. That combination — price falling while OI builds — is classified as Short Buildup. Fresh short positions are being added on weakness, which historically prefaces further downside until shorts are forced to cover. The stock's option PCR sits at 0.65, indicating heavy call-side writing — option dealers see resistance overhead. Max-pain strike at ₹1,800 sits 0.6% above the current price, a mild magnet near expiry.

There have been no notable bulk or block deals from FIIs, mutual funds, or insurance companies in Sun Pharmaceutical Industries Ltd. over the last 30 sessions.

Putting it together, the smart-money picture for Sun Pharmaceutical Industries Ltd. suggests further downside pressure is likely.

F&O Positioning EOD derivatives setup

Buildup Class
Short Buildup
bias: bearish
Futures OI
24,197,600
+325500 (+1.4%)
Option PCR (OI)
0.65
neutral option setup
Max Pain Strike
₹ 1,800
writer loss minimized strike

Quote Details key metrics & weights

Previous Close
₹ 1,789.90
yesterday's EOD close
Index Contribution
-0.001 pp
contribution to Nifty
Traded Volume
4,209,769
live shares traded today
Upcoming Earnings
no report scheduled

Key Fundamentals headline ratios · Healthcare

P/E (TTM)
37.4
price / earnings
P/B
5.5
price / book
ROE
14.7%
return on equity
Market Cap
₹ 429,121 Cr
total market value
Dividend Yield
0.92%
trailing yield
EPS (TTM)
₹ 47.79
earnings per share

Fundamental ratios sourced from public market data, refreshed periodically; verify against company filings before relying on them.

Institutional Deals last 30 sessions (bulk & block)

No institutional bulk or block deals recorded for this stock in the last 30 sessions.

Insider & Promoter Filings last 60 days

No insider disclosures filed for this stock in the last 60 days.

Option Chain Ladder nearest expiry 2026-06-30 · spot 1,788 · EOD 2026-06-03

Option writers expect range between 1,800 and 1,900+6.2% upside, +0.6% downside.
unbalanced
Call OI (writers) Strike Put OI (writers)
2,450 +1k
IV 29% Δ 0.85 θ -0.9 ν 1
1660
22,750 +12k
1,400
IV 28% Δ 0.82 θ -0.9 ν 1
1680
276,850 -19k
19,950 +7k
IV 24% Δ 0.81 θ -0.8 ν 1
1700
434,350 +4k
IV 19% Δ -0.14 θ -0.3 ν 1
0
IV 39% Δ 0.68 θ -1.5 ν 2
1720
359,800 -1k
IV 18% Δ -0.18 θ -0.4 ν 1
147,700 -5k
IV 21% Δ 0.73 θ -0.8 ν 2
1740
625,100 +17k
IV 17% Δ -0.24 θ -0.4 ν 2
174,300 +55k
IV 20% Δ 0.66 θ -0.9 ν 2
1760
978,950 +36k
IV 17% Δ -0.31 θ -0.4 ν 2
264,950 +64k
IV 20% Δ 0.58 θ -0.9 ν 2
1780
267,050 +26k
IV 16% Δ -0.40 θ -0.4 ν 2
1,448,300 +46k
IV 19% Δ 0.50 θ -0.8 ν 2
1800 S MP
1,047,550 +39k
IV 15% Δ -0.51 θ -0.4 ν 2
258,650 -2k
IV 19% Δ 0.41 θ -0.8 ν 2
1820
263,900 +24k
IV 15% Δ -0.61 θ -0.3 ν 2
626,850 +29k
IV 19% Δ 0.33 θ -0.7 ν 2
1840
371,000 -30k
IV 15% Δ -0.72 θ -0.2 ν 2
622,650 +16k
IV 19% Δ 0.26 θ -0.6 ν 2
1860
284,550 -40k
IV 14% Δ -0.81 θ -0.1 ν 1
612,850
IV 19% Δ 0.20 θ -0.5 ν 1
1880
140,350
IV 10% Δ -0.96 θ +0.2 ν 0
2,093,350 +82k
IV 20% Δ 0.15 θ -0.5 ν 1
1900 R
206,500 +13k

Chain Interpretation

Spot Underlying 1,788.50
Key Resistance (R) 1,900
Key Support (S) 1,800
Max Pain Strike (MP) 1,800
Concentrations of Option open interest show strong barrier levels. Option writers defend these levels, especially heading into monthly derivatives expiry.

Strategy Builder multi-leg payoff for SUNPHARMA options · 2026-06-30 expiry

Underlying: SUNPHARMA · Spot: ₹ 1,788.50 · Expiry: 2026-06-30 · Lot: 350

Legs

Side
Type
Strike
Qty
Premium
Net premium
Max profit
Max loss
Breakevens
Position Delta
Position Theta/day
Position Vega/1% IV

Payoff at expiry

Latest News recent coverage from Reuters, Simply Wall St, MT Newswires and others